Genor Biopharma : announces the appointment of several world-renowned experts to its Scientific Advisory Board

28 Dec, 2021

Genor Biopharma announces the appointment of several world-renowned experts to its Scientific Advisory Board

Shanghai, China, December 28, 2021 - Genor Biopharma (Stock code: 6998.HK) today announced the appointment of several world-renowned experts in tumor immunology & clinical oncology to its Scientific Advisory Board (SAB). They are:

• Alex A. Adjei, Professor of Oncology and Pharmacology at the Mayo Clinic, USA NCI Board of Scientific Counsellors
• Zhijian CHEN, National Academy of Sciences, Professor at the University of Texas Southwestern Medical Center;
• Yangxin FU, Endowed Professor at Tsinghua University.
• David Kerr, CBE (Commander of the British Empire), British Academy of Medical Sciences, Professor of Cancer Medicine at the University of Oxford;
• Leonard Saltz, Professor, Weill Cornell Medical College and Attending Physician and Member, Memorial Sloan Kettering Cancer Center;
• John F. Seymour, AM (Member of the Order), Australian Academy of Health and Medical Sciences, Professor at the Peter MacCallum Cancer Centre & Royal Melbourne Hospital;
• John R. Zalcberg, OAM (Medal of the Order), Professor of Medicine at Monash University;

(Alphabetical order of surnames)

"We are honored to invite world leading tumor immunologists & clinical oncology key opinion leaders from China, the United States, the United Kingdom and Australia to become members of the Genor Biopharma Scientific Advisory Board (SAB)," said Dr. Feng GUO,Chairman of the Boardand Chief Executive Officer, Genor Biopharma."Their participation will accelerate the pace of the company's global innovation, provide valuable inputs on Genor's FIC potential and differentiated pipelines, and support the rapid advance of candidate drugs into clinical development in China, the United States and Australia."

• Alex A. Adjei, Professor of Oncology and Pharmacology at the Mayo Clinic. He is the Leader of the Thoracic Oncology Program and Head of Mayo Clinic's Early Cancer Therapeutics Program. He is also a member of the National Cancer Institute's Board of Scientific Counsellors. He is Editor-in-Chief of the Journal of Thoracic Oncology and JTO CRR. His research includes drug development, regulatory science and early-phase clinical trials. Dr. Adjei works to bring promising new compounds from the laboratory to initial human testing and to ultimately gain regulatory approval for their use in patients. He was awarded the 2012-2017 ASCO Drug Discovery Award for his work in cancer drug development. He also received the Adi Gazdar Merit Award for his research and mentorship in lung cancer from the International Association for the Study of Lung Cancer (IASLC) and the Lifetime Achievement Award from ESMO.

• Zhijian CHEN, Professor at the University of Texas Southwestern Medical Center and investigator at the Howard Hughes Medical Institute. He was elected to the National Academy of Sciences in 2014 and received the Breakthrough Prize in Life Sciences in 2018. Dr. Chen is mainly engaged in research of cell signaling and innate immunity, and has made a series of breakthroughs discoveries in innate immune responses to DNA and RNAs.

• Yangxin FU, Tsinghua University endowed Professor. Dr. Fu is an internationally renowned cancer immunologist who has pioneered novel immunotherapeutic approaches against cancer including methods to potentiate conventional cancer treatments. His team has made the following major contributions to the tumor-treatment and tumor-immunology fields: The therapeutic effect of ablative irradiation (IR) depends on innate and adaptive immune responses: bridging DNA damage to DNA sensing for increased CTL-mediated tumor regression. Blockade of oncogenic receptor signaling induces stress signals that trigger innate and adaptive immunity for tumor regression. New strategies to recruit and activate DC and lymphocytes into tumor tissues can greatly enhance immunotherapy. Recently, his team has designed new cytokines and antibodies that target and activate immune cells in tumor microenvironment.

• David Kerr CBE (Commander of the British Empire), Professor of Cancer Medicine at the University of Oxford. He is a former President of the European Society of Oncology (ESMO) and a fellow of the British Academy of Medical Sciences. Dr. Kerr has an international reputation for the treatment of and research into colorectal cancer and received the Harvard Medal of Global Health: Distinguished Leadership Award for organizing and initiating the INDOX and AfrOx programs, which bring together the world's top oncologists to guide and help improve outcomes and reduce mortality in patients with cancer in India and Africa.

• Leonard Saltz, Professor, Weill Cornell Medical College and Attending Physician and Member, Memorial Sloan Kettering Cancer Center, where he is Executive Director for Clinical Value & Sustainability, and formerly Chief of the Gastrointestinal Oncology service and Head of the Colorectal Oncology Section. One of the leading physicians in colorectal cancers in the United States, Dr. Saltz has an extensive experience in cancer drug development, and has published over 300 manuscripts, reviews and editorials. He also has expertise in rare gastrointestinal tumors such as gastrointestinal and pancreatic neuroendocrine tumors, and other digestive tract cancers such as liver, pancreatic, gastric and esophageal cancers. He also treats other neuroendocrine tumors, such as adrenocortical cancers and pheochromocytomas.

• John F. Seymour, AM (Member of the Order), Professor at the Peter MacCallum Cancer Centre & Royal Melbourne Hospital. Professor John Seymour AM is a clinical haematologist and Director of the Department of Haematology of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia. Professor Seymour is the co-chair of the federal ministerial Blood Cancer Taskforce and a member of several national and international scientific committees including, the Scientific Boards of the International Workshop on chronic lymphocytic leukemia (CLL), and Hairy Cell Leukemia Foundation, Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group. In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.

• John R. Zalcberg, OAM (Medal of the Order), Professor of Medicine at Monash University. He is a co-founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), Dr. Zalcberg is a previous Board Member of Cancer Trials Australia, Co-Chair of the Cancer Drugs Alliance and immediate past Chair of the Australian Clinical Trials Alliance. Dr. Zalcberg's clinical research interests include gastrointestinal cancer, gastrointestinal stromal tumors and new drug development. He has received the Medal of the Order of Australia Award (OAM) and the 2011 Cancer Achievement Award from the Medical Oncology Group of Australia.

The experts joining the Genor Biopharma Scientific Advisory Board have vast experience in tumor immunology and oncology clinical research, and have globally recognized academic status, which is an effective complement to the existing scientific team of the company.

At the same time, the participation of the world's top scientists reflects their high recognition of Genor Biopharma's research and development philosophy, scientific research strength and continuous exploration.